ManolioT. A., “Implementing Genomic Medicine in the Clinic: The Future Is Here,”Genetics in Medicine15, no. 4 (2013): 258–267.
2.
See ACMG Board of Directors, “Points to Consider for Informed Consent for Genome/Exome Sequencing,”Genetics in Medicine15, no. 9 (2013): 748–749;.
3.
AyusoC., “Informed Consent for Whole-Genome Sequencing Studies in the Clinical Setting: Proposed Recommendations on Essential Content and Process,”European Journal of Human Genetics21, no. 10 (2013): 1054–1059;.
HendersonG. E., “Is Informed Consent Broken?”American Journal of the Medical Sciences342, no. 4 (2011): 267–272;.
6.
KronenthalC.DelaneyS. K.ChristmanM. F., “Broadening Research Consent in the Era of Genome-Informed Medicine,”Genetics in Medicine14, no. 4 (2012): 432–436;.
7.
McGuireA. L.BeskowL. M., “Informed Consent in Genomics and Genetic Research,”Annual Review of Genomics and Human Genetics11 (2010): 361–381;.
8.
OrmondK. E., “Challenges in the Clinical Application of Whole-Genome Sequencing,”The Lancet375, no. 9727 (2010): 1749–1751;.
SharpR. R., “Downsizing Genomic Medicine: Approaching the Ethical Complexity of Whole-Genome Sequencing by Starting Small,”Genetics in Medicine13, no. 3 (2011): 191–194;.
11.
TrinidadS. B., “Informed Consent in Genome-Scale Research: What Do Prospective Participants Think?”AJOB Primary Research3, no. 3 (2012): 3–11.
12.
ACMG Board of Directors, “Points to Consider in the Clinical Application of Genomic Sequencing,”Genetics in Medicine14, no. 8 (2012): 759–761.
13.
GreenR. C., “ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing,”Genetics in Medicine15, no. 7 (2013): 565–574;.
14.
American College of Medical Genetics and Genomics (ACMG), “Incidental Findings in Clinical Genomics: A Clarification,” Genetics in Medicine15, no. 8 (2013): 664–666.
15.
See, e.g., BurkeW., “Recommendations for Returning Genomic Incidental Findings? We Need To Talk!”Genetics in Medicine15, no. 11 (2013): 854–859;.
16.
McEwenJ. E.BoyerJ. T.SunK. Y., “Evolving Approaches to the Ethical Management of Genomic Data,”Trends in Genetics29, no. 6 (2013): 375–382;.
Presidential Commission for the Study of Bioethical Issues, Anticipate and Communicate: Ethical Management of Incidental and Secondary Findings in the Clinical, Research, and Direct-to-Consumer Contexts, December 2013, available at <http://bioethics.gov/sites/default/files/FINALAnticipateCommunicate_PCSBI_0.pdf>(last visited July 30, 2014);.
19.
WolfS. M.AnnasG. J.EliasS., “Point-Counterpoint. Patient Autonomy and Incidental Findings in Clinical Genomics,”Science340, no. 6136 (2013): 1049–1050.
AllenC.FoulkesW. D., “Qualitative Thematic Analysis of Consent Forms Used in Cancer Genome Sequencing,”BMC Medical Ethics12, no. 1 (2011): 14.
23.
See National Human Genome Research Institute (NHGRI), “Clinical Sequencing Exploratory Research,” available at <http://www.genome.gov/27546194>(last visited July 30, 2014).
24.
See WolfS. M., “Managing Incidental Findings and Research Results in Genomic Research Involving Biobanks and Archived Data Sets,”Genetics in Medicine14, no. 4 (2012): 361–384.
25.
See KnoppersB. M.ZawatiM. H.KirbyE. S., “Sampling Populations of Humans Across the World: ELSI Issues,”Annual Review of Genomics and Human Genetics13 (2012): 395–413.
26.
National Human Genome Research Institute (NHGRI), “Informed Consent for Genomics Research,” available at <http://www.genome.gov/27026588>(last visited July 30, 2014).
27.
See AllenFoulkes, supra note 8.
28.
See Manolio, supra note 1.
29.
See Green, supra note 4.
30.
Id., at 567.
31.
See ACMG, supra note 6.
32.
See KannryJ. L.WilliamsM. S., “Integration of Genomics into the Electronic Health Record: Mapping Terra Incognita,”Genetics in Medicine15, no. 10 (2013): 757–760;.
33.
HazinR., “Ethical, Legal, and Social Implications of Incorporating Genomic Information into Electronic Health Records,”Genetics in Medicine15, no. 10 (2013): 810–816.
34.
Paasche-OrlowM. K., “Readability of Consent Form Templates: A Second Look,”IRB35, no. 4 (2013): 12–19.